2 Information about lenalidomide

Table 1 Information about lenalidomide

Marketing authorisation

Lenalidomide (Revlimid; Celgene) in combination with dexamethasone has a marketing authorisation for treating 'multiple myeloma in adult patients who have received at least one prior therapy'. It also has a marketing authorisation for 'previously untreated multiple myeloma in people who are not eligible for transplant'.

Dosage in the marketing authorisation

The recommended starting dosage is 25 mg orally once daily on days 1 to 21 of repeated 28‑day cycles.


Lenalidomide is available as a 21‑capsule pack. The cost per pack (excluding VAT; British National Formulary online, accessed April 2019) varies according to capsule size: £3,426.00 (2.5 mg), £3,570.00 (5 mg), £3,675.00 (7.5 mg), £3,780.00 (10 mg), £3,969.00 (15 mg), £4,168.50 (20 mg) and £4,368.00 (25 mg).

The company has a commercial arrangement. This makes lenalidomide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)